Although our understanding of the heterogeneity of breast cancers has improved that has led to the generation of novel anti-cancer therapies exploiting the hormone receptor status, epigenetic marks, and other biological machineries, yet, when it comes to the general population there has been very limited success owing to the individual differences among the patients. This evidence concerns the gene NR4A1 and breast cancer.